प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Quince Therapeutics: A-T में eDSP के लिए Phase 3 NEAT टॉपलाइन डेटा 2026 की पहली तिमाही में अपेक्षित
The company completed enrollment of the pivotal Phase 3 NEAT trial (105 total participants) and confirmed that topline results will be reported in Q1 2026. The trial remains under an FDA Special Protocol Assessment, and positive data would support an NDA submission planned for H2 2026.
मुख्य तथ्य
स्रोत का अंश
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report